BriaCell治疗技术公司通过供应疫苗筹集了3.05M美元,支持其癌症免疫疗法研究。 BriaCell Therapeutics raises $3.05M through a stock offering, supporting its cancer immunotherapy research.

BriaCell治疗公司是一家研制癌症免疫疗法的生物技术公司,它宣布公开提供762 500股股票,每股4美元,共筹集约305万美元。 BriaCell Therapeutics, a biotech firm developing cancer immunotherapies, announced a public stock offering of 762,500 shares at $4.00 each, raising about $3.05 million. 这些资金将支持周转资本、公司目标和预先业务计划。 The funds will support working capital, corporate goals, and advance business plans. 尽管在报告其转移性乳腺癌治疗药物 Bria-OTS 的积极临床结果后，股价最近飙升了 20%，但该股后来下跌了 4.71%。 Despite a recent 20% stock price surge after reporting positive clinical results for its metastatic breast cancer treatment, Bria-OTS, the stock later fell by 4.71%. 只有ThinkEquity是这次招标的唯一代理商. ThinkEquity is the sole placement agent for this offering.